Login to Your Account



Clinic Roundup


Monday, December 27, 2010
Myrexis Inc., of Salt Lake City, started a Phase IIb trial of Azixa (verubulin), a small molecule designed to act as a microtubule destabilizing agent, in front-line glioblastoma multiforme. The study will enroll up to 120 newly diagnosed patients and test Azixa plus standard of care vs. standard of care alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription